GlaxoSmithKline (GSK) Earns “Hold” Rating from Shore Capital
GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating restated by equities researchers at Shore Capital in a research note issued on Thursday.
Several other equities research analysts also recently issued reports on the company. J P Morgan Chase & Co reissued a “neutral” rating and issued a GBX 1,330 ($17.81) price objective on shares of GlaxoSmithKline in a research note on Thursday. UBS raised GlaxoSmithKline to a “buy” rating and set a GBX 1,550 ($20.76) price objective for the company in a research note on Monday. HSBC reissued a “buy” rating and issued a GBX 1,925 ($25.78) price objective on shares of GlaxoSmithKline in a research note on Wednesday, November 22nd. Jefferies Group reduced their price objective on GlaxoSmithKline from GBX 1,540 ($20.62) to GBX 1,450 ($19.42) and set a “buy” rating for the company in a research note on Thursday, November 16th. Finally, Investec downgraded GlaxoSmithKline to a “hold” rating and cut their price target for the stock from GBX 1,800 ($24.11) to GBX 1,390 ($18.62) in a research note on Monday, November 6th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of GBX 1,584.29 ($21.22).
Shares of GlaxoSmithKline (LON:GSK) traded down GBX 28 ($0.37) during trading on Thursday, reaching GBX 1,279.50 ($17.14). The company had a trading volume of 16,252,826 shares, compared to its average volume of 11,220,000. GlaxoSmithKline has a 1 year low of GBX 1,291.50 ($17.30) and a 1 year high of GBX 1,724.50 ($23.09).
In related news, insider Urs Rohner bought 473 shares of the business’s stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($20.33) per share, for a total transaction of £7,180.14 ($9,615.83). Also, insider Simon Dingemans bought 1,076 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The shares were bought at an average price of GBX 1,527 ($20.45) per share, with a total value of £16,430.52 ($22,004.18). Insiders have bought a total of 1,576 shares of company stock worth $2,400,376 in the last three months.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.